APLT:NSD-Applied Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 9.03

Change

+0.28 (+3.20)%

Market Cap

USD 1.04B

Volume

1.94M

Analyst Target

USD 55.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Address: 545 Fifth Avenue, New York, NY, United States, 10017

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ALNY Alnylam Pharmaceuticals Inc

-3.20 (-1.12%)

USD 36.83B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B

ETFs Containing APLT

SURI Simplify Propel Opportuni.. 12.23 % 0.00 %

+0.55 (+0%)

N/A
SANE 5.51 % 0.00 %

N/A

N/A
BBC Virtus LifeSci Biotech Cl.. 1.28 % 0.79 %

-0.55 (0%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 169.55% 68% D+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 169.55% 68% D+ 84% B
Trailing 12 Months  
Capital Gain 289.22% 69% C- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 289.22% 69% C- 85% B
Trailing 5 Years  
Capital Gain -46.63% 34% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.63% 34% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain 41.39% 77% C+ 86% B+
Dividend Return 41.39% 77% C+ 86% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 170.29% 24% F 13% F
Risk Adjusted Return 24.31% 81% B- 57% F
Market Capitalization 1.04B 81% B- 72% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector